Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22143099 | 0.90 | BTN3A1 (0.34) | RIPK1 | |
| SCHEMBL23034485 | 0.87 | BTN3A1 (0.38) | RIPK1 | |
| SCHEMBL20078704 | 0.84 | BTN3A1 (0.35) | RIPK1 | |
| SCHEMBL25511597 | 0.84 | BTN3A1 (0.35) | RIPK1 | |
| SCHEMBL23819281 | 0.83 | HPRT1 (0.36) | HPRT1ALDH1A1RIPK1SERPINA3 | |
| SCHEMBL26289173 | 0.83 | HPRT1 (0.36) | HPRT1ALDH1A1RIPK1SERPINA3 | |
| SCHEMBL20078682 | 0.82 | BTN3A1 (0.31) | RIPK1 | |
| SCHEMBL22646524 | 0.82 | BTN3A1 (0.31) | RIPK1 | |
| SCHEMBL26651183 | 0.78 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL21342879 | 0.77 | TMPRSS2 (0.41) | HPRT1ALDH1A1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11266666-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | HPRT1 12/4885ALDH1A1 1121/4885KDM4E 2278/4885 |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | HPRT1 12/4885ALDH1A1 1121/4885KDM4E 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.